Table 1 Chronogram and investigations of the ARPEGE study
Inclusion | Weekly follow-up during RT | 3 months after RT | Once/year during the 5 first years | Every 2 years during the 10 next first | End of study (15 years) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Written Informed consent signature | X | ||||||||||||
Checking of inclusion and non-inclusion criteria | X | ||||||||||||
Inclusion | X | ||||||||||||
Clinical exam | X | X | X | X | X | X | X | X | X | X | X | X | X |
Medical history | X | ||||||||||||
Biopsy | X | ||||||||||||
Blood sample | X | ||||||||||||
Toxicity recording | X | X | X | X | X | X | X | X | X | X | X | X | |
Biopsy-related adverse events recording | X | X | X | X | X | X | X | X | X | X | X | X | |
Blood sample-related adverse events recording | X | X | X | X | X | X | X | X | X | X | X | X | |
Concurrent treatments recording | X | X | X | X | X | X | X | X | X | X | X | X | X |